Localization of Potential Binding Sites for the Edema Disease Verotoxin (VT2e) in Pigs

Canadian Journal of Veterinary Research

Volumn 62, Issue 2, 1998, Pages 81-86

  Waddell, Thomas E ^a,b   Coomber, Brenda L ^a   Gyles, Carlton L ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Health of Animals Laboratory   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; ENTEROTOXIN; VEROTOXIN 2;

ANIMAL; ARTICLE; BINDING SITE; ESCHERICHIA COLI; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; SWINE; SWINE DISEASE; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; BACTERIAL TOXINS; BINDING SITES; EDEMA DISEASE OF SWINE; ENDOTHELIUM, VASCULAR; ENTEROTOXINS; ESCHERICHIA COLI; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH, VASCULAR; SHIGA-LIKE TOXIN II; SWINE; TISSUE DISTRIBUTION;

EID: 0032043936     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. LINGOOD MA, THOMPSON JM. Verotoxin production among porcine strains of Escherichia coli and its association with oedema disease. J Med Microbiol 1987; 25: 359-362.
2. MACLEOD DL, GYLES CL, WILCOCK BP. Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet Pathol 1991; 28: 66-73.
3. SHOONDERWOERD M, CLARKE RC, van DREMEL AA, RAWLUK SA. Colitis in calves: Natural and experimental infection with a verotoxin-producing strain of Escherichia coli O111 NM Can J Vet Res 1988; 52: 484-487.
4. KARMALI MA. Infection by Verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 1989; 2: 15-38.
5. MOAKE JL. Haemolytic-uraemic syndrome Basic science. Lancet 1994; 343: 393-397.
6. GYLES CL. Escherichta cali cytotoxins and enterotoxins. Can J Microbiol 1992; 38: 734-746.
7. BERTSCHINGER HU, NIELSEN NO. Edema Disease: Diseases of Swine. Ames: Iowa State University Press, 1992: 498-509.
8. FRANKE S, HARMSEN D, CAPRILI A, PIERARD D, WIELER LH, KARCH H. Clonal relatedness of Shiga-like toxinproducing Escherichia coli strains of human and porcine origin. J Clin Micro 1995; 33: 3174-3178.
9. OBRIG TG, DELVECCHIO PJ, BROWN JE, MORAN TP, ROWLAND BM, JUDGE TK, ROTHMAN SW. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988; 56: 2732-2738.
10. TESH VL, SAMUEL JE, PERERA LP, SHAREFKIN B, O'BRIEN AD. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis 1991; 164: 344-52.
11. van de KAR HCAJ, MONNENS LAH, KARMALI MA, VAN HINSBERGH VMW. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80: 2755-2764.
12. COHEN A, MADRID-MARINA V, ESTROV Z, FREEDMAN MH, LINGWOOD CA, DOSCH HM. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: A mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol 1990; 2: 1-8.
13. ROBINSON LA, HURLEY RM, LINGWOOD C, MATSELL DG. Escherichia coli verotoxin binding to human paediatric glomerular mesangial cells. Pediatr Nephrol 1995; 6: 700-704.
14. MOBASSALEH M, DONOHUEROLFE A, JACEWICZ M, GRAND RJ, KEUSCH GT. Pathogenesis of Shigella diarrhea: Evidence for a developmentally regulated glycolipid receptor for shigella toxin involved in the fluid secretory response of rabbit small intestine, J Infect Dis 1988; 157: 1023-1031.
15. WADDELL T, COHEN A, LINGWOOD C. Reconstitution of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci USA 1990; 87: 7898-7901.
16. BOYD B, TYRRELL M, MALONEY M, GYLES C, BRUNTON J, LINGWOOD C. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targeting and results in a verotoxin 1-like disease in pigs. J Exp Med 1993; 177: 1745-1753.
17. KEUSCH GT, JACEWICZ M, ACHESON DWK, DONOHUE-ROLFE A, KANE AV, MCCLUER RH. Globotriaosylceramide. Gb3, is an alternative receptor for Shiga-hke toxin 2e. Infect Immun 1995; 63: 1138-1341.
18. KURTZ HJ, BERGELAND ME, BARNES DM. Pathologic changes in edema disease of swine. Am J Vet Res 1969; 30: 791-806.
19. OHSHIMA KI, MIURA S. Pathological study on an occurrence of swine edema disease in Iwate prefecture in 1959. Jap J Vet Sci 1961; 23: 111-121.
20. WADDELL T, LINGWOOD CA, GYLES CL. Interaction of verotoxin 2e with pig intestine. Infect Immun 1996; 64: 1714-1719.
21. MACLEOD DL, GYLES CL. Purification and characterization of an Escherichia coli Shiga-like toxin II variant. Infect Immun 1990; 58: 1232-1239.
22. GILLARD BK, THURMON LT, MARCUS DM. Association of glyco-sphingolipids with intermediate filamenis of mesenchymal, epithelial, glial, and muscle cells. Cell Motil Cytoskeleton 1992; 21: 255-271.
23. RICHARDSON SE, ROTMAN TA, JAY V, SMITH CR, BECHER LE, PETRIC M, OLIVIERI NF, KARMALI MA. Experimental verocytotoxemia in rabbits. Infect Immun 1992; 60: 4154-4167.
24. ZOJA C, CORNA D, FARINA C, SACCHE G, LINGWOOD C, DOYLE MP, PADHYE W, ABBATE M, REMUZZI G. Verotoxin glycolipid receptors determine the localization of microangiopathic processes in rabbits given verotoxin-1. J Lab Clin Invest 1992; 120: 229-238.
25. TESH VL, BURRIS JA, OWENS JW, GORDON VM, WADOLKOWSKI EA, O'BRIEN AD, SAMUEL JE. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 1993; 61: 3392-3402.
26. LINGWOOD CA. Verotoxin-bmding in human renal sections. Nephron 1994; 66: 21-28.
27. EKLID K, OLSNES S. Interaction of Shigella shigae cytotoxin with receptors on sensitive and insensitive cells. J Recept Res 1980; 1: 199-213.
28. JACEWICZ M, CLAUSEN H, NUDELMAN E, DONOHUE-ROLFE A, KEUSCH GT. Pathogenesis of Shigella diarrhea XI. Isolation of Shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 1986; 163: 1391-1404.
29. PUDYMAITIS A, LINGWOOD CA. Susceptibility to verotoxin as a function of the cell cycle. J Cell Physiol 1992; 150: 632-639.
30. SAMUEL J, PERERA LP, WARD S, O'BRIEN AD, GINSBERG V, KRIVAN HC. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shisa-like toxin II variants. Infect Immun 1990; 58: 611-618.
31. GILLARD BK, JONES MA, TURNER AA, LEWIS DE, MARCUS DM. Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids. Arch Biochem Biophys 1990; 279: 122-129.
32. GILLARD BK, HEALTH JP, THURMON LT, MARCUS DM. Association of glyco-sphingolipids with intermediate filaments of mesenchymal, epithelial, glial, and muscle cells. Cell Motil Cytoskeleton 1992; 21: 255-271.
33. METHYIAPUN S, POHLENZ SFL, BERTSCHINGER HU. Ultrastructure of the intestinal mucosa in pigs experimentally inoculated with an edema diseaseproducing strain of Escherichia coli (0139;K12:H1). Vet Pathol 1984; 21: 516-520.
34. TESH VL, RAMEGOWDA B, SAMUEL JE. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages Infect Immun 1994; 62: 5085-5094.
35. KAYE SA, LOUISE CB, BOYD B, LINGWOOD CA, OBRIG TG. Shiga toxin-associated hemolytic uremic syndrome: Interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993; 61: 3886-3891.
36. LOUISE CB, OBRIG TG. Shiga toxin-associated hemolytic-uremic syndrome: Combined cytotoxic effects of Shiga toxin. interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 1991; 59: 4173-4179.
37. LOUISE CB, OBRIG TG. Shiga toxinassociated hemolytic uremic syndrome: Combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 1992; 60: 1536-1543.